New drug tested to shrink prostate cancer before surgery
NCT ID NCT06613100
Summary
This early-stage study is testing a new drug called xaluritamig in men with intermediate or high-risk prostate cancer that hasn't spread. The main goal is to see if it's safe to give the drug before planned surgery to remove the prostate. Researchers will check if the treatment causes side effects and if surgery can still be performed safely afterward.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109-1023, United States
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Universitaetsklinikum Essen
RECRUITINGEssen, 45147, Germany
-
Universitaetsklinikum Hamburg Eppendorf
RECRUITINGHamburg, 20246, Germany
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.